HeimNCYT • LON
add
Novacyt SA
Við síðustu lokun
37,80 GBX
Dagbil
37,10 GBX - 37,35 GBX
Árabil
36,00 GBX - 69,00 GBX
Markaðsvirði
30,58 m. EUR
Meðalmagn
49,10 þ.
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
EPA
Viðskiptafréttir
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (GBP) | jún. 2025info | Breyting á/á |
|---|---|---|
Tekjur | 4,90 m. | -1,80% |
Rekstrarkostnaður | 6,43 m. | -63,28% |
Nettótekjur | -3,17 m. | 64,17% |
Hagnaðarhlutfall | -64,76 | 63,51% |
Hagnaður á hvern hlut | — | — |
EBITDA | -2,17 m. | 39,84% |
Virkt skatthlutfall | 3,80% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (GBP) | jún. 2025info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 23,72 m. | -28,01% |
Heildareignir | 62,92 m. | -36,70% |
Heildarskuldir | 22,08 m. | -23,82% |
Eigið fé alls | 40,84 m. | — |
Útistandandi hlutabréf | 70,63 m. | — |
Eiginfjárgengi | 0,65 | — |
Arðsemi eigna | -12,63% | — |
Ávöxtun eigin fjár | -15,34% | — |
Peningaflæði
Breyting á handbæru fé
| (GBP) | jún. 2025info | Breyting á/á |
|---|---|---|
Nettótekjur | -3,17 m. | 64,17% |
Handbært fé frá rekstri | -2,74 m. | 39,76% |
Reiðufé frá fjárfestingum | -85,50 þ. | 84,91% |
Reiðufé frá fjármögnun | -555,00 þ. | -28,92% |
Breyting á handbæru fé | -3,37 m. | 39,31% |
Frjálst peningaflæði | -1,26 m. | 88,95% |
Um
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
Framkvæmdastjóri
Stofnsett
3. júl. 2006
Vefsvæði
Starfsfólk
234
